Navigation Links
Nanogea Announces New Scientific Advisory Board Members
Date:10/9/2009

Nanogea Adds Drs. C. Thomas Caskey and Saul Tendler to its Scientific Advisory Board

Westlake Village, Calif. (PRWEB) October 9, 2009 -- Nanogea, a nano-biotech company focused on commercializing the industry's most sensitive single molecular detection platform, is pleased to announce today that Dr. C. Thomas Caskey and Dr. Saul Tendler have joined its scientific advisory board.

Dr. Caskey is a prominent medical geneticist and biomedical entrepreneur. Dr. Caskey presently serves as Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, a research institute that seeks to investigate the cause of human diseases at the cellular and molecular levels using DNA and protein technologies to expose disease mechanisms. He is a former founding Director and CEO of Cogene Biotech Ventures, venture capital funds designed to support early-stage biotechnology and life science companies. Dr. Caskey is a former SVP for Res. at Merck and Trustee and President of the Merck Genome Res. Inst. as well as an Ex-Chief of Section of Medical Genetics and Professor of Medicine and Biochemistry, Baylor College of Medicine. He sits on the boards of Essex Woodlands Health Ventures, Luminex, Odyssey Thera, En Vivo, Metabolon, Genome Canada, LabCorp. of America, and Vice Chair of Genome Canada. Dr. Caskey is a member of the Academy of Medicine, Engineering and Science of Texas (President of TAMEST 2004-05), a member of the National Academy of Sciences, and the Institute of Medicine. Dr. Caskey received his medical doctorate from Duke University. He is Board certified in Internal Medicine, Clinical Genetics, Metabolic Diseases, and Molecular Diagnostics.

Dr. Saul Tendler is Pro-Vice-Chancellor, Professor of Biophysical Chemistry and Head of the School of Pharmacy, University of Nottingham. His expertise is in the field of biophysical chemistry, with a particular focus on analysis of biomolecular systems and their interactions. Dr. Tendler is a Fellow of the Royal Society of Chemistry, and was designated a Fellow of the Royal Pharmaceutical Society of Great Britain in 2000. Dr. Tendler received his Ph.D. from the University of Aston and his Bachelors of Science (First Class Honours) in Pharmacy at the University of Manchester.

"We are delighted to have a distinguished panel of advisors such as Drs. Caskey and Tendler," said Mr. David Sun, President and CEO of Nanogea, "Their extraordinary expertise and background will help guide Nanogea's research and development in the foreseeable future as we expedite our development effort to commercialize our first clinical application for CML (Chronic Myelogeous Leukemia) detection, based on our proprietary NanoCone™ chemistry and NE-AFM™ platform."

About Nanogea
Nanogea, a nano-biotech company located in Westlake Village California, is focused on commercializing the industry's most sensitive genomic and proteomic detection platform based on its innovative NanoCone™ chemistry and NanoCone Enabled Atomic Force Microscopy (NE-AFM™ ) technology. The Company is utilizing its technology to push the genetic and protein detection limit to the single molecular level, thus greatly improving the sensitivity and accuracy of disease diagnosis, prognosis, treatment, and monitoring as well as drug discovery research. To learn more about our pioneering technology, visit www.nanogea.com.

Nanogea Corporation
5716 Corsa Avenue, Suite 201
Westlake Village, CA 91362.
Phone: (818) 889-0538    Fax: (818) 889-0816
E-mail: mlowrey(at)nanogea(dot)com
Website: www.nanogea.com

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3017444.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. CardioDx Announces Appointment of Dr. Louis G. Lange as Chairman of the Board of Directors
2. IridoTech Announces IridoLab Self Service Kiosk
3. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
4. NCIIA Announces New Undergraduate Competition
5. Sangamo Announces Pricing of Public Offering of Common Stock
6. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
7. Verenium Announces Proposed Public Offering of Common Stock
8. Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
9. YM BIOSCIENCES ANNOUNCES OFFER FOR CYTOPIA LTD., AN AUSTRALIAN CANCER-FOCUSED DEVELOPMENT COMPANY
10. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):